The Supervisory Board of JENOPTIK AG has decided to reappoint Dr. Stefan Traeger as Chairman of the Executive Board for a further three years with effect from July 1, 2025 and has extended his contract, which runs until June 30, 2025, until June 30, 2028.
“Under the leadership of Dr. Traeger, Jenoptik has been very successful in recent years in developing into a profitably growing, focused photonics group. Continuity in the management of the company by Dr. Traeger creates the basis for realizing the organic growth potential and thus consistently implementing our strategy,” said Matthias Wierlacher, Chairman of the Supervisory Board of JENOPTIK AG.
“I look forward to continuing to work with my colleagues on the Executive Board, employees, customers and shareholders and thank the Supervisory Board for the trust they have placed in me,” said Dr. Stefan Traeger. “I would like to continue the successful path we have embarked on together”.
Together with the other members of the Executive Board, Dr. Stefan Traeger has been shaping the strategic realignment and focus of the company since 2017. The core of the “More Value” agenda is to focus Jenoptik's leading technological expertise on the fast-growing future markets of semiconductor & electronics, life science & medical technology and smart mobility. As an “enabler”, the company can create significant added value (“More Value”) for customers, employees and shareholders with its photonic solutions and accordingly achieve above-average growth and an increase in profitability.
This press release may contain statements relating to the future which are based on current assumptions and forecasts made by the corporate management of the Jenoptik Group. A variety of known and unknown risks, uncertainties, and other factors may cause the actual results, the financial situation, the development, or the performance of the company to diverge significantly from the information provided here. Such factors may include geopolitical conflicts, changes in currency exchange rates and interest rates, pandemics, the introduction of competing products, or a change in business strategy. The company does not assume any obligation to update such forward-looking statements in the light of future developments.
“Under the leadership of Dr. Traeger, Jenoptik has been very successful in recent years in developing into a profitably growing, focused photonics group. Continuity in the management of the company by Dr. Traeger creates the basis for realizing the organic growth potential and thus consistently implementing our strategy,” said Matthias Wierlacher, Chairman of the Supervisory Board of JENOPTIK AG.
“I look forward to continuing to work with my colleagues on the Executive Board, employees, customers and shareholders and thank the Supervisory Board for the trust they have placed in me,” said Dr. Stefan Traeger. “I would like to continue the successful path we have embarked on together”.
Together with the other members of the Executive Board, Dr. Stefan Traeger has been shaping the strategic realignment and focus of the company since 2017. The core of the “More Value” agenda is to focus Jenoptik's leading technological expertise on the fast-growing future markets of semiconductor & electronics, life science & medical technology and smart mobility. As an “enabler”, the company can create significant added value (“More Value”) for customers, employees and shareholders with its photonic solutions and accordingly achieve above-average growth and an increase in profitability.
This press release may contain statements relating to the future which are based on current assumptions and forecasts made by the corporate management of the Jenoptik Group. A variety of known and unknown risks, uncertainties, and other factors may cause the actual results, the financial situation, the development, or the performance of the company to diverge significantly from the information provided here. Such factors may include geopolitical conflicts, changes in currency exchange rates and interest rates, pandemics, the introduction of competing products, or a change in business strategy. The company does not assume any obligation to update such forward-looking statements in the light of future developments.
